Research and Markets Breast Cancer Changing Treatment Paradigms for Local And Locally Advanced Breast Cancer



May 5, 2005 -- Research and Markets (http://www.researchandmarkets.com/reports/c16792) has announced the addition of Breast Cancer - Changing Treatment Paradigms For Local And Locally Advanced Breast Cancer to their offering

Anthracycline-based regimens and tamoxifen are well-established in the treatment of early-stage breast cancer . In recent days, however, agents such as Sanofi-Aventiss Taxotere and AstraZenecas Arimidex have been gaining prominence. This report examines the current treatment paradigms for early-stage breast cancer , based on primary research data from 180 physicians in the seven major markets.

This report provides an analysis of current treatment practices for early-stage breast cancer based on primary research from 180 physicians in the seven major markets. The extent of use of antihormonal agents, such as anti-estrogens and aromatase inhibitors, in local and locally-advanced breast cancer is examined. Physician awareness and ratings of late-stage pipeline drugs for breast cancer , including recently launched APPs Abraxane and GSKs lapatinib are included in the report together with coverage of adjuvant and neoadjuvant chemotherapy in early-stage breast cancer , including the commonly used regimens in each setting

Report Highlights:
Sanofi-Aventiss Taxotere (docetaxel) is likely to see a significant increase in its use as adjuvant and neoadjuvant therapies in combination with anthracycline-based regimens. However, Sanofi-Aventis will need to disseminate relevant trial results to physicians to compete with the likes of paclitaxel, especially in the US.

AstraZenecas Arimidex (anastrozole) will replace tamoxifen as the gold-standard adjuvant therapy for local and locally advanced breast cancer , given the latest ATAC trial results in December 2004.

Abraxane (albumin-bound paclitaxel) had the highest awareness rate among late-stage pipeline drugs, as well as being considered the most promising agent. Its recent launch and potential success in metastatic disease is likely to be translated into the adjuvant and neoadjuvant settings.

Reasons to Purchase:
- Identify the key chemotherapy regimens in the neoadjuvant and adjuvant settings for local and locally-advanced breast cancer

- Target physicians effectively through an understanding of prescribing behavior for antihormonal agents in pre- and postmenopausal breast cancer

- Evaluate product potential by assessing physician awareness and rating of key late-stage pipeline drugs for breast cancer

For more information visit http://www.researchandmarkets.com/reports/c16792

Laura Wood
Senior Manager
Research and Markets
e-mail protected from spam bots
Fax: +353 1 4100 980





Research and Markets Breast Cancer Changing Treatment Paradigms for Local And Locally Advanced Breast Cancer